Global In Vivo Electroporation Instrument Market

Global In Vivo Electroporation Instrument Market is estimated to be US$ 230.43 million by 2030 with a CAGR of 6.1% during the forecast period
COVINA, Calif. - July 14, 2021 - PRLog -- Competitive Landscape:

The key players operating in the global In vivo electroporation instrument market includes Thermo Fisher Scientific, Inc., Merck, Lonza group, BEX, Celetrix LLC., Eppendorf AG, Harvard Bioscience Inc., Maxcyte Inc., Mirus Bio LLC, and Bio Rad laboratories. The companies are focusing on acquisitions and collaboration strategies to strengthen its market, which is expected to fuel the markets growth.

The Global Biometric Sensors Market accounted for US$  128 Million 2020 and is estimated to be US$ 230.43 million by 2030 and is anticipated to register a CAGR of 6.1%. Electroporation is a biotechnological procedure that involves passing an electric current through a live surface, such as a cell or a molecule. Pores emerge on the surface of the living structure in this fashion, allowing biological material to pass through readily. This method is commonly used to introduce viruses or plasmids into cells via pores in the cell membrane in the form of vectors or plasmids. . Electroporation of the cell membrane occurs when cells are exposed to an electric field, and it has been researched and employed in a variety of applications in medicine and food biotechnology (e.g. electrochemotherapy, gene electrotransfer, extraction of biomolecules). Electroporation in vivo has become a popular method for creating nonviral gene treatments and nucleic acid vaccinations (NAV).

The report "Global In Vivo Electroporation Instrument Market, By Application (Biomedical research and Therapeutics), By End-user (Biotechnology and Pharmaceuticals company, Hospital, Academic Research and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030"

Key Highlights:
  • In June 2021, Mirai Medical Ltd, a manufacturer of a precision cancer therapy platform, announced the first procedures at Rigshospitalet, University of Copenhagen, Denmark in a clinical trial to evaluate the safety of Calcium electroporation treatment with EndoVEĀ®, and ePOREĀ® a novel breakthrough technology that can treat gastrointestinal cancers endoscopically.
  • In July 2021, Inovio Pharmaceuticals discovers, develops, and delivers a new generation of diseases, called DNA vaccines, focused on cancers and infectious diseases. The company's electroporation DNA delivery technology uses brief, controlled electrical pulses to increase cellular DNA vaccine uptake.
  • To know the upcoming trends and insights prevalent in this market, click the link below:


Media Contact
Shweta Raskar
1 860 531 2701
Email:*** Email Verified
Tags:In Vivo Electroporation
Location:Covina - California - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse

Like PRLog?
Click to Share